Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...
Tris Pharma has reported positive outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol to treat moderate-to-severe ...
The drug candidate is administered orally in the form of tablet. It acts by targeting nociceptin/orphanin-FQ peptide (NOP) receptors. The drug candidate was under development for the treatment of ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果